Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Abemaciclib (LY2835219) Plus Fulvestrant sammenlignet med Placebo Plus Fulvestrant ved tidligere behandlet brystkreft (postMONARCH)

3. oktober 2026 oppdatert av: Eli Lilly and Company

postMONARCH: En randomisert, dobbeltblind, placebokontrollert, fase 3-studie for å sammenligne effekten av Abemaciclib Plus Fulvestrant med Placebo Plus Fulvestrant hos deltakere med HR+, HER2-, avansert eller metastatisk brystkreft etter progresjon på en CDK4 & 6-hemmer og endokrin Terapi

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

368

Fase

  • Fase 3

Utvidet tilgang

Godkjent for salg til publikum. Se utvidet tilgangspost.

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • San Juan, Argentina, 5400
        • CER San Juan
    • Buenos Air
      • Buenos Aires, Buenos Air, Argentina, C1426ABP
        • Fundación Respirar
      • Ciudad Autónoma de Buenos Aire, Buenos Air, Argentina, C1027AAP
        • Centro de Investigaciones Metabólicas (CINME)
    • Buenos Aires F.D.
      • CABA, Buenos Aires F.D., Argentina, 1125
        • Fundación Cenit Para La Investigación En Neurociencias
    • Córdoba Province
      • Río Cuarto, Córdoba Province, Argentina, 5800
        • Instituto Médico Río Cuarto
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
        • Centro Medico San Roque
      • Namur, Belgia, 5000
        • CHU UCL Namur/Site Sainte Elisabeth
    • Antwerpen
      • Brasschaat, Antwerpen, Belgia, 2930
        • Algemeen Ziekenhuis klina
    • Limburg
      • Hasselt, Limburg, Belgia, 3500
        • Jessa Ziekenhuis
    • Capital Region
      • Copenhagen, Capital Region, Danmark, 2730
        • Herlev and Gentofte Hospital
    • Central Jutland
      • Herning, Central Jutland, Danmark, 7400
        • Regionshospitalet Gødstrup
    • Arizona
      • Phoenix, Arizona, Forente stater, 85004
        • St. Joseph's Hospital and Medical Center
    • Arkansas
      • Springdale, Arkansas, Forente stater, 72762
        • Highlands Oncology Group
    • California
      • Fullerton, California, Forente stater, 92835
        • Providence Medical Foundation
      • Los Alamitos, California, Forente stater, 90720
        • Cancer and Blood Specialty Clinic
      • Los Angeles, California, Forente stater, 90033
        • Keck School of Medicine of USC
      • Los Angeles, California, Forente stater, 90024
        • TRIO-US (Translational Research in Oncology-US)
      • Santa Monica, California, Forente stater, 90404
        • UCLA Hematology/Oncology - Parkside
      • Sylmar, California, Forente stater, 91342
        • Olive View-UCLA Medical Center
      • Torrance, California, Forente stater, 90505
        • Torrance Memorial Physician Network / Cancer Care
      • Whittier, California, Forente stater, 90602
        • PIH Health Hematology Medical Oncology
    • Colorado
      • Denver, Colorado, Forente stater, 80220
        • Rocky Mountain Cancer Center - Hale Parkway
    • Florida
      • Fort Myers, Florida, Forente stater, 33901-8101
        • Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
      • Hollywood, Florida, Forente stater, 33024
        • Millennium Oncology Research Clinic
      • Miami, Florida, Forente stater, 33136
        • University of Miami Hospital and Clinics, Sylvester Cancer Center
      • Pensacola, Florida, Forente stater, 32503
        • Woodlands Medical Specialists, PA
      • Sarasota, Florida, Forente stater, 34232
        • Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
      • West Palm Beach, Florida, Forente stater, 33401
        • Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Winship Cancer Institute, Emory University
      • Gainesville, Georgia, Forente stater, 30501
        • Northeast Georgia Medical Center
      • Macon, Georgia, Forente stater, 31201
        • Central Georgia Cancer Care
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96826
        • Kapiolani Medical Center for Women and Children
    • Illinois
      • Harvey, Illinois, Forente stater, 60426
        • Ingalls Memorial Hospital
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70809
        • Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
      • Lake Charles, Louisiana, Forente stater, 70601
        • Clinical Trials of SWLA
    • Maine
      • Lewiston, Maine, Forente stater, 04240
        • Central Maine Medical Center
    • Maryland
      • Baltimore, Maryland, Forente stater, 21237
        • Mfsmc-Hjwci
      • Clinton, Maryland, Forente stater, 20735
        • Maryland Oncology Hematology, P.A. - Clinton
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Forente stater, 02215
        • Dana Farber Cancer Institute
      • Danvers, Massachusetts, Forente stater, 01923
        • MGH Northshore Cancer Center
      • Fairhaven, Massachusetts, Forente stater, 02719
        • Southcoast Centers for Cancer Care
      • Foxborough, Massachusetts, Forente stater, 02035
        • Dana-Farber Cancer Institute - Foxborough
      • Methuen, Massachusetts, Forente stater, 01844
        • Dana Farber Cancer Center Merrimack Valley
      • Milford, Massachusetts, Forente stater, 01757
        • Dana Farber Cancer Institute
      • Newton, Massachusetts, Forente stater, 02462
        • Mass General Cancer Center
      • South Weymouth, Massachusetts, Forente stater, 02190
        • Dana Farber Cancer Institute
      • Worcester, Massachusetts, Forente stater, 01606
        • Reliant Medical Group
    • Montana
      • Billings, Montana, Forente stater, 59102
        • St. Vincent Frontier Cancer Center
    • New Hampshire
      • Londonderry, New Hampshire, Forente stater, 03053
        • Dana Farber Cancer Center Londonderry
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • University of New Mexico Comprehensive Cancer Center
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02906
        • Lifespan Cancer Institute
    • Tennessee
      • Chattanooga, Tennessee, Forente stater, 37404
        • Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
      • Nashville, Tennessee, Forente stater, 37203
        • Sarah Cannon Research Institute/SCRI
      • Nashville, Tennessee, Forente stater, 37203
        • Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
    • Texas
      • Bedford, Texas, Forente stater, 76022
        • Texas Oncology - Bedford
      • Denton, Texas, Forente stater, 76201
        • Texas Oncology - Denton
      • El Paso, Texas, Forente stater, 79902
        • Texas Oncology, P.A.
      • Houston, Texas, Forente stater, 77030-4009
        • University of Texas MD Anderson Cancer Center
      • McKinney, Texas, Forente stater, 75071
        • Texas Oncology - McKinney
      • McKinney, Texas, Forente stater, 75071
        • Woodlands Medical Specialists, PA
      • Mesquite, Texas, Forente stater, 75150
        • Woodlands Medical Specialists, PA
      • Plano, Texas, Forente stater, 75093
        • Texas Oncology-Plano West
      • Plano, Texas, Forente stater, 75075-7787
        • Texas Oncology - Plano East
      • San Antonio, Texas, Forente stater, 78229
        • Mays Cancer Center
      • The Woodlands, Texas, Forente stater, 77380
        • US Oncology
      • Tyler, Texas, Forente stater, 75702
        • Texas Oncology - Tyler Cancer Center
    • Utah
      • Murray, Utah, Forente stater, 84107
        • Intermountain Medical Center
      • St. George, Utah, Forente stater, 84790
        • Intermountain Healthcare - St. George
    • Vermont
      • Burlington, Vermont, Forente stater, 05401
        • The University of Vermont Medical Center Inc.
    • Virginia
      • Winchester, Virginia, Forente stater, 22601
        • Shenandoah Oncology, P.C.
    • Aquitaine
      • Bordeaux, Aquitaine, Frankrike, 33076
        • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
    • Finistère
      • Brest, Finistère, Frankrike, 29609
        • CHRU de Brest
    • Loire-Atlantique
      • Nantes, Loire-Atlantique, Frankrike, 44277
        • Hôpital privé du Confluent SAS
    • Vendée
      • La Roche-sur-Yon, Vendée, Frankrike, 85000
        • CHD Vendee
      • Thessaloniki, Hellas, 546 45
        • Euromedica General Clinic of Thessaloniki
    • Achaḯa
      • Pátrai, Achaḯa, Hellas, 26504
        • University Hospital of Patras
    • Attikí
      • Athens, Attikí, Hellas, 115 28
        • Alexandra Hospital
    • Irakleío
      • Heraklion, Irakleío, Hellas, 711 10
        • University General Hospital of Heraklion
    • Central District
      • Kfar Saba, Central District, Israel, 4428164
        • Meir Medical Center
      • Petah Tikva, Central District, Israel
        • Rabin Medical Center
      • Ramat Gan, Central District, Israel, 5265601
        • Sheba Medical Center
    • Jerusalem
      • Jerusalem, Jerusalem, Israel, 9112001
        • Hadassah Medical Center
    • Southern District
      • Beersheba, Southern District, Israel, 8400000
        • Soroka Medical Center
    • Tell Abīb
      • Tel Aviv, Tell Abīb, Israel, 6423906
        • Sourasky Medical Center
      • Bari, Italia, 70124
        • Instituto Tumori Giovanni Paolo II
      • Grosseto, Italia, 58100
        • Ospedale Misericordia di Grosseto
      • Milan, Italia, 20132
        • Ospedale San Raffaele
      • Viterbo, Italia, 01100
        • ASL Viterbo Ospedale Belcolle
    • Catania
      • Misterbianco, Catania, Italia, 95045
        • Humanitas Istituto Clinico Catanese
    • Emilia-Romagna
      • Meldola, Emilia-Romagna, Italia, 47014
        • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
    • Friuli Venezia Giulia
      • Udine, Friuli Venezia Giulia, Italia, 33100
        • P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
    • Estado de Baja California
      • Mexicali, Estado de Baja California, Mexico, 21200
        • Centro de Investigacion en Artritis y Osteoporosis SC
      • Tijuana, Estado de Baja California, Mexico, 22010
        • COI Tijuana - Centro Oncológico Internacional
    • Jalisco
      • Guadalajara, Jalisco, Mexico, 45647
        • Centro Oncológico Internacional (COI)
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 64060
        • Centro Regiomontano de Investigación
    • San Luis Potosí
      • San Luis Potosí City, San Luis Potosí, Mexico, 78209
        • Oncologico Potosino, S.C.
    • Masovian Voivodeship
      • Otwock, Masovian Voivodeship, Polen, 05-400
        • Europejskie Centrum Zdrowia - Oddzial Onkologii
    • Opole Voivodeship
      • Opole, Opole Voivodeship, Polen, 45-060
        • Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
      • Badajoz, Spania, 06006
        • Hospital Infanta Cristina
      • Madrid, Spania, 28009
        • Hospital General Universitario Gregorio Marañon
      • Toledo, Spania, 45007
        • Hospital Universitario de Toledo
    • A Coruña [La Coruña]
      • A Coruña, A Coruña [La Coruña], Spania, 15006
        • CHUAC-Hospital Teresa Herrera
    • Balears [Baleares]
      • Palma, Balears [Baleares], Spania, 07120
        • Hospital Universitari Son Espases
    • Barcelona [Barcelona]
      • Barcelona, Barcelona [Barcelona], Spania, 08003
        • Parc de Salut Mar - Hospital del Mar
    • Catalunya [Cataluña]
      • Barcelona, Catalunya [Cataluña], Spania, 08036
        • Hospital Clínic de Barcelona
    • Murcia, Región de
      • El Palmar, Murcia, Región de, Spania, 30120
        • Hospital Clínico Universitario Virgen de la Arrixaca
    • Málaga
      • Málaga, Málaga, Spania, 29011
        • H.R.U Málaga - Hospital Materno-infantil
    • Navarre
      • Pamplona, Navarre, Spania, 31009
        • Complejo Hospitalario de Navarra
    • Tarragona [Tarragona]
      • Reus, Tarragona [Tarragona], Spania, 43204
        • Hospital Universitari Sant Joan de Reus
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, Spania, 46017
        • Hospital Universitario Doctor Peset
    • Stockholms
      • Stockholm, Stockholms, Sverige, 171 76
        • Karolinska Universitetssjukhuset Solna
    • Örebro Län [se-18]
      • Örebro, Örebro Län [se-18], Sverige, 701 85
        • Universitetssjukhuset Örebro
    • Kyǒnggi-do
      • Seongnam, Kyǒnggi-do, Sør -Korea, 13620
        • Seoul National University Bundang Hospital
    • Seoul-teukbyeolsi [Seoul]
      • Seoul, Seoul-teukbyeolsi [Seoul], Sør -Korea, 02841
        • Korea University Anam Hospital
      • Seoul, Seoul-teukbyeolsi [Seoul], Sør -Korea, 08308
        • Korea University Guro Hospital
    • Taegu-Kwangyǒkshi
      • Daegu, Taegu-Kwangyǒkshi, Sør -Korea, 41404
        • Kyungpook National University Chilgok Hospital
      • Kaohsiung City, Taiwan, 80756
        • Kaohsiung Medical University Hospital
      • New Taipei City, Taiwan, 231
        • Taipei Tzu Chi General Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Taipei, Taiwan, 10449
        • Mackay Memorial Hospital
      • Taoyuan, Taiwan, 333
        • Chang Gung Medical Foundation-Linkou Branch
    • Tainan
      • Tainan, Tainan, Taiwan, 71004
        • Chi Mei Medical Center
      • Hradec Králové, Tsjekkia, 500 05
        • Fakultni nemocnice Hradec Kralove
    • Pardubice Region
      • Pardubice, Pardubice Region, Tsjekkia, 53203
        • Multiscan
      • Adana, Tyrkia (Türkiye), 01370
        • Adana City Hospital
      • Ankara, Tyrkia (Türkiye), 06520
        • Memorial Ankara Hastanesi
      • Ankara, Tyrkia (Türkiye), 06010
        • Ankara Gülhane Eitim ve Aratrma Hastanesi
      • Diyarbakır, Tyrkia (Türkiye), 21200
        • Dicle Üniversitesi
      • Edirne, Tyrkia (Türkiye), 22030
        • Trakya University
      • Istanbul, Tyrkia (Türkiye), 34722
        • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
      • Malatya, Tyrkia (Türkiye), 44280
        • İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
    • Konya
      • Meram, Konya, Tyrkia (Türkiye), 42080
        • Necmettin Erbakan Meram Medical Fac.
    • İzmir
      • Cordaleo, İzmir, Tyrkia (Türkiye), 009035575
        • Izmir Medical Park Hospital
      • Budapest, Ungarn, 1122
        • Országos Onkológiai Intézet
      • Budapest, Ungarn, 1062
        • Magyar Honvedseg Egeszsegugyi Kozpont
    • Bács-Kiskun county
      • Kecskemét, Bács-Kiskun county, Ungarn, 6000
        • Bacs-Kiskun Megyei Korhaz
    • Győr-Moson-Sopron
      • Győr, Győr-Moson-Sopron, Ungarn, 9024
        • Petz Aladar Egyetemi Oktato Korhaz

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer

  • Have radiologic evidence of disease progression or recurrence either

    • On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
    • On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
  • Must be deemed appropriate for treatment with ET

  • If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression

  • Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)

  • Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)

  • Have adequate renal, hematologic, and hepatic organ function

  • Must be able to swallow capsules/tablets

Exclusion Criteria:

  • Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
  • Have symptomatic or untreated central nervous system metastasis
  • Have received any systemic therapy between disease recurrence/progression and study screening
  • Have received more than 1 line of therapy for advanced or metastatic disease.
  • Have received prior chemotherapy for metastatic breast cancer (MBC)
  • Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A: Abemaciclib plus Fulvestrant

Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.

Administered orally.

Administered IM.

Aktiv komparator: Arm B: Placebo plus Fulvestrant

Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met.

Administered IM.

Administered orally.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-Free Survival (PFS)
Tidsramme: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)

PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Tidsramme: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)

PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first.

Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Tidsramme: Randomization until measured progressive disease (Up to 22 Months)

ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions.

Randomization until measured progressive disease (Up to 22 Months)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

11. mars 2022

Primær fullføring (Faktiske)

8. februar 2024

Studiet fullført (Antatt)

1. desember 2027

Datoer for studieregistrering

Først innsendt

22. desember 2021

Først innsendt som oppfylte QC-kriteriene

22. desember 2021

Først lagt ut (Faktiske)

27. desember 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD-delingstidsramme

Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Tilgangskriterier for IPD-deling

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere